In theory, the principles of omnichannel – personalised content through the right channels to maximise customer experience – ...

Pfizer’s Braftovi (encorafenib) regimen has been granted accelerated approval by the US Food and Drug Administration (FDA) to ...

As the world’s third largest pharmaceutical market, Japan accounted for approximately 6% of the $1.5tn in global ...

If you are struggling to navigate the complexity of early commercialisation, rest assured, you are not alone. Clinical trial ...

Gilead Sciences’ seladelpar has been recommended by the European Medicines Agency’s human medicines committee to treat the ...

Amgen’s Blincyto (blinatumomab) has been granted a licence extension by the Medicines and Healthcare products Regulatory ...

Elevate your MedEd strategy with our 2025 toolkit! From AI-driven patient avatars to interactive augmented reality scenarios, ...

Is your medical education strategy reaching the right HCPs in the formats they prefer? Discover actionable insights to ...

Novartis will be gaining exclusive global rights to PTC Therapeutics’ mid-stage Huntington’s disease (HD) programme in a deal worth up to $2.9bn. The candidate, PTC518, was discovered from PTC’s ...

AstraZeneca’s Tagrisso (osimertinib) has been approved by the European Commission (EC) to treat a new subset of lung cancer ...

Presenting your brand strategy for review by your most senior colleagues is a big deal, both professionally and personally.